Immune Pharmaceuticals Stock Book Value Per Share
Immune Pharmaceuticals fundamentals help investors to digest information that contributes to Immune Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Immune OTC Stock. The fundamental analysis module provides a way to measure Immune Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immune Pharmaceuticals otc stock.
Immune |
Immune Pharmaceuticals OTC Stock Book Value Per Share Analysis
Immune Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Immune Pharmaceuticals Book Value Per Share | 0.02 X |
Most of Immune Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immune Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Immune Pharmaceuticals is about 0.02 times. This is 101.18% lower than that of the Healthcare sector and 99.84% lower than that of the Drug Manufacturers - Major industry. The book value per share for all United States stocks is 100.0% higher than that of the company.
Immune Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immune Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Immune Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Immune Pharmaceuticals by comparing valuation metrics of similar companies.Immune Pharmaceuticals is currently under evaluation in book value per share category among related companies.
Immune Fundamentals
| Return On Asset | -42.63 | |||
| Current Valuation | 8.67 M | |||
| Shares Outstanding | 72.38 M | |||
| Shares Owned By Insiders | 2.16 % | |||
| Shares Owned By Institutions | 0.06 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | (0.17) X | |||
| Price To Book | 0.40 X | |||
| Price To Sales | 858.11 X | |||
| Revenue | 19 K | |||
| EBITDA | (13.77 M) | |||
| Net Income | (34.39 M) | |||
| Cash And Equivalents | 76 K | |||
| Total Debt | 8.33 M | |||
| Debt To Equity | 989.50 % | |||
| Current Ratio | 0.02 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (14.69 M) | |||
| Short Ratio | 1.32 X | |||
| Earnings Per Share | (1.15) X | |||
| Beta | 2.99 | |||
| Market Capitalization | 553.21 K | |||
| Total Asset | 36.18 M | |||
| Retained Earnings | (62.99 M) | |||
| Working Capital | (1.45 M) | |||
| Current Asset | 4.83 M | |||
| Current Liabilities | 6.29 M | |||
| Z Score | -1.4 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Immune OTC Stock
If you are still planning to invest in Immune Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Pharmaceuticals' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |